Kymera Therapeutics has announced the launch of a new program targeting the IRF5 transcription factor, enhancing its portfolio of oral immunology treatments for autoimmune and rheumatic diseases. The ...
The MarketWatch News Department was not involved in the creation of this content. BOSTON, June 25, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and ...
WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (KYMR) (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results